Pakistan's Drug Regulatory Authority (Drap) issued an urgent medical product alert ordering the immediate withdrawal of a contaminated batch of Anarob Infusion, a widely-used intravenous antibiotic containing metronidazole. The recall was triggered after Drap's Central Drugs Laboratory determined that batch H24219 contained bacterial endotoxin levels exceeding safety specifications, classifying the product as substandard.
Critical Safety Concerns
Anarob Infusion is commonly administered in hospitals to treat serious bacterial infections affecting the stomach, skin, lungs, joints, and other body systems when oral antibiotics prove ineffective. The contaminated batch poses significant health risks to patients, particularly those already vulnerable due to hospitalization or compromised immune systems.
"Use of this contaminated infusion may cause severe adverse reactions such as fever, chills, septic shock and life-threatening complications. Hospitalised and immunocompromised patients are at the greatest risk," Drap warned in its official alert.
Comprehensive Recall Measures
The regulatory authority has implemented extensive measures to ensure complete removal of the defective product from Pakistan's healthcare system. Drap's field force and Provincial Drug Control departments received immediate directives to conduct comprehensive market surveys targeting the identification and removal of batch H24219.
All pharmacists and chemists operating at distribution centers and retail pharmacies must immediately inspect their inventory, cease distribution of the affected batch, and quarantine remaining stocks for return to the supplier. The authority has also mandated increased surveillance across all federating units to guarantee effective recall implementation.
Healthcare Provider Responsibilities
Healthcare facilities, pharmacies, and supply chain operators have been instructed to exercise heightened vigilance in identifying potentially affected inventory. Any adverse reactions or quality issues associated with the drug must be reported to Pakistan's National Pharmacovigilance Centre using designated reporting mechanisms.
Patients who have received treatment with products bearing the affected batch number are advised to contact their healthcare providers immediately if they experience any complications potentially related to the contaminated infusion. All incidents should be reported to both Drap and the National Pharmacovigilance Centre for comprehensive safety monitoring.
Regulatory Context
This recall represents part of Drap's ongoing efforts to maintain pharmaceutical safety standards in Pakistan's healthcare system. The authority previously directed similar recalls, including a pediatric fever syrup withdrawal in March of the previous year, demonstrating consistent enforcement of drug quality regulations when safety concerns arise.
